Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) released its earnings results on Monday, May, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.09 million. Bellicum Pharmaceuticals had a negative return on equity of 49.65% and a negative net margin of 19,399.12%. The company's revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. View Bellicum Pharmaceuticals' Earnings History.

8 equities research analysts have issued twelve-month price targets for Bellicum Pharmaceuticals' stock. Their forecasts range from $18.00 to $32.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $26.81 in the next year. View Analyst Ratings for Bellicum Pharmaceuticals.

Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (3/16/2017)
• 2. Cantor Fitzgerald analysts commented, "Following Bellicum's 4Q16 earnings conference call, we are reiterating our Overweight rating and $32 price target. Bellicum provided several updates outlining its plans for 2017, including: 1) progress in its current BP-004 trial with BPX-501 in malignant and non-malignant pediatric transplant patients, 2) greater clarity from the FDA on the development path of BPX-501 in the U.S., and 3) updates on its expanding CAR and TCR oncology programs. Looking forward, we expect additional updated data at the European Hematology Association (EHA) meeting being held in June and an update on the finalized U.S. registration trial design in mid-2017." (3/14/2017)
• 3. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)

Bellicum Pharmaceuticals saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 3,579,907 shares, an increase of 9.0% from the April 13th total of 3,284,379 shares. Based on an average trading volume of 518,829 shares, the short-interest ratio is currently 6.9 days.

Some companies that are related to Bellicum Pharmaceuticals include Five Prime Therapeutics (FPRX), Esperion Therapeutics (ESPR), La Jolla Pharmaceutical Company (LJPC), Albany Molecular Research (AMRI), Acorda Therapeutics (ACOR), TG Therapeutics (TGTX), Aduro BioTech (ADRO), Omeros (OMER), Anika Therapeutics (ANIK), Keryx Biopharmaceuticals (KERX), MacroGenics (MGNX), Aclaris Therapeutics (ACRS), Cytokinetics (CYTK), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Enanta Pharmaceuticals (ENTA), Paratek Pharmaceuticals (PRTK) and Calithera Biosciences (CALA).

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (15.20%), FMR LLC (10.53%), JPMorgan Chase & Co. (8.24%), Vanguard Group Inc. (3.91%), Foresite Capital Management III LLC (3.38%) and Kennedy Capital Management Inc. (2.33%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Eventide Asset Management LLC, Morgan Stanley, Highbridge Capital Management LLC, Credit Suisse AG, Suffolk Capital Management LLC, TD Asset Management Inc. and ProShare Advisors LLC. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, LMR Partners LLP, Sphera Funds Management LTD., Vanguard Group Inc., Monashee Investment Management LLC, Kennedy Capital Management Inc., Renaissance Technologies LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $12.35.